Medinol
CompanyIsrael
Medinol develops 2 assets, the furthest in human trials (ChampioNIR Ridaforolimus Eluting Peripheral Stent System in popliteal artery stenosis). Mostly device acting on mTOR signalling and MTOR; based in Israel.
- 2
- Assets
- Furthest stage
- Human trials
- 2
- Trials
- 2
- Signals
Pipeline
2ChampioNIR Ridaforolimus Eluting Peripheral Stent System
Maintains arterial patency and releases ridaforolimus to inhibit mTOR-mediated cell proliferation and reduce restenosis.
Human trials, Device, mTOR signalling, MTOR, popliteal artery stenosis, superficial femoral artery stenosis
IoNIR Ridaforolimus-Eluting Coronary Stent System
Releases ridaforolimus to inhibit MTOR and vascular smooth muscle proliferation, limiting restenosis while supporting the coronary artery.
Human trials, Device, mTOR signalling, MTOR, coronary artery disease, coronary stenosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Signals2
- Similar companies6